- Veracyte Announces First Quarter 2024 Financial Results
- 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
- Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
- New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
- Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
- Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
- Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
More ▼
Key statistics
As of last trade, Veracyte Inc (VCYT:NMQ) traded at 20.79, 11.69% above the 52 week low of 18.61 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.77 |
---|---|
High | 20.87 |
Low | 20.72 |
Bid | 20.76 |
Offer | 20.85 |
Previous close | 20.63 |
Average volume | 678.53k |
---|---|
Shares outstanding | 76.45m |
Free float | 75.80m |
P/E (TTM) | -- |
Market cap | 1.58bn USD |
EPS (TTM) | -1.02 USD |
Data delayed at least 15 minutes, as of May 10 2024 14:35 BST.
More ▼